Boyd Watterson Asset Management LLC OH Sells 17 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Boyd Watterson Asset Management LLC OH lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 919 shares of the biopharmaceutical company’s stock after selling 17 shares during the quarter. Boyd Watterson Asset Management LLC OH’s holdings in Regeneron Pharmaceuticals were worth $807,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of REGN. FMR LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares during the last quarter. abrdn plc lifted its holdings in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock worth $193,136,000 after acquiring an additional 186,215 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after buying an additional 122,103 shares during the period. Finally, TD Asset Management Inc increased its stake in Regeneron Pharmaceuticals by 64.4% in the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock worth $148,353,000 after buying an additional 70,628 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $7.48 during trading on Friday, reaching $883.20. The company had a trading volume of 505,652 shares, compared to its average volume of 431,865. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The firm has a 50-day simple moving average of $948.00 and a 200-day simple moving average of $893.63. The company has a market cap of $96.94 billion, a price-to-earnings ratio of 25.42, a price-to-earnings-growth ratio of 2.56 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the business posted $10.96 EPS. The business’s quarterly revenue was up .6% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Finally, UBS Group raised their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $977.77.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at approximately $17,540,472.04. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now directly owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,022 shares of company stock worth $10,552,991. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.